7 European Projects Found
Searched on 125080 European Projects
FINISHED
REgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lomber SPINE unresponsive to conventional therapy (RESPINE)
Start date: Jan 1, 2017, End date: Dec 31, 2020,
...s. In addition, MRI T2 relaxation measurements demonstrated a significant improvement. To develop the world’s first rigorously proven, effective treatment of DDD, RESPINE aims to assess, via a multicentre, randomized, controlled, phase 2b clinical trial including 112 patients with DDD, the efficacy of an allogenic intervertebral mesenchymal stem cell (MSC)-based therapy. This innovative therapy ai ...
Read Project
18
Partners Participants
FINISHED
THE MILESTONE PROJECT: Managing the Link and Strengthening Transition from Child to Adult Mental Health Care (MILESTONE)
Start date: Feb 1, 2014, End date: Jan 31, 2019,
Transition to adulthood is the period of onset of most of the serious mental disorders that disable or kill in adult life. Current service configuration of distinct Child and Adolescent Mental Health (CAMHS) and Adult Mental Health (AMHS) Services is considered the weakest link where the care pathway should be most robust. Transition-related discontinuity of care is a major socioeconomic and socie ...
Read Project
14
Partners Participants
FINISHED
Clinical trial of autologous adipose-derived mesenchymal stromal cells (ASC) in the treatment of mild to moderate osteoarthritis (ADIPOA2)
Start date: Jan 1, 2015, End date: Dec 31, 2018,
...(ASCs) are attractive for cellular therapy given the abundance of tissue, high frequency of MSCs and minimally invasive harvest procedure. The EU consortium ADIPOA has shown in a ‘first in man’ 2-centre Phase I safety study that intraarticular injection of a single dose of autologous ASCs to the knee (18 patients, 12 month follow-up) was well-tolerated, had no adverse effects, and resulted in an i ...
Read Project
20
Partners Participants
FINISHED
COMPACT BIOPHOTONIC PLATFORM FOR DRUG ALLERGY DIAGNOSIS (COBIOPHAD)
Start date: Jan 1, 2016, End date: Dec 31, 2018,
Drug hypersensitivity to antibiotics, mainly Beta-lactams (BLCs) affects more than 2.5 million European citizens. Moreover, preventable adverse drug reactions are estimated in additional hospitalization costs of 1750-4500 €/patient. Currently, the allergy diagnosis is mainly based on the information given by invasive, single, and risky in vivo assays. In daily practice, few in vitro diagnostic met ...
Read Project
11
Partners Participants
FINISHED
I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly (I-MOVE-plus)
Start date: May 1, 2015, End date: Oct 31, 2018,
The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share val ...
Read Project
33
Partners Participants
FINISHED
BeTheCuRE (BTCURE)
Start date: Apr 1, 2011, End date: Mar 31, 2017,
BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Read Project
41
Partners Participants
FINISHED
Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics (Mitotarget)
Start date: Feb 1, 2009, End date: Mar 31, 2012,
Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question re ...
Read Project
